SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

Please provide your email address to receive an email when new articles are posted on . “Robotics combines science, engineering and technology to design, construct, operate and use machines programmed ...

Please provide your email address to receive an email when new articles are posted on . Age-related dementia, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy and hearing ...

Children with nontraumatic cataracts undergoing implantation of a secondary intraocular lens (IOL) after lensectomy are at a risk for complications including a diagnosis of glaucoma and visual axis ...